Thrombocytopenia differential diagnosis: Difference between revisions
Line 15: | Line 15: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
! colspan=" | ! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan="10" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings | ! colspan="10" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
Line 22: | Line 22: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ||
! colspan=" | ! colspan="3" rowspan="2" |Symptoms | ||
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | | colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
|- | |- | ||
Line 28: | Line 28: | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
|- | |- | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ||
Line 56: | Line 55: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 86: | Line 84: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 116: | Line 113: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 146: | Line 142: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 178: | Line 173: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 208: | Line 202: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 237: | Line 230: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 266: | Line 258: | ||
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ||
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 296: | Line 287: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 326: | Line 316: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 356: | Line 345: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 386: | Line 374: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 416: | Line 403: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Alport syndrome | ! align="center" style="background:#DCDCDC;" + |Alport syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 446: | Line 432: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 479: | Line 464: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 517: | Line 501: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ||
Line 543: | Line 526: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 573: | Line 555: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 603: | Line 584: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 634: | Line 614: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 665: | Line 644: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 695: | Line 673: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 725: | Line 702: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 757: | Line 733: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 785: | Line 760: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 814: | Line 788: | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Parasitism|Parasitic infections]] | ! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Parasitism|Parasitic infections]] | ||
! align="center" style="background:#DCDCDC;" + |[[Malaria]] | ! align="center" style="background:#DCDCDC;" + |[[Malaria]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 844: | Line 817: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |[[Babesiosis]] | ! align="center" style="background:#DCDCDC;" + |[[Babesiosis]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 883: | Line 855: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ||
Line 915: | Line 886: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 950: | Line 920: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 974: | Line 943: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,004: | Line 972: | ||
| align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent [[Bone marrow suppression|myelosuppression]] | | align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent [[Bone marrow suppression|myelosuppression]] | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,033: | Line 1,000: | ||
! align="center" style="background:#DCDCDC;" + |[[Over-the-counter drug|OTC agents]] | ! align="center" style="background:#DCDCDC;" + |[[Over-the-counter drug|OTC agents]] | ||
! align="center" style="background:#DCDCDC;" + |[[Quinine]]-containing beverages | ! align="center" style="background:#DCDCDC;" + |[[Quinine]]-containing beverages | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,066: | Line 1,032: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,094: | Line 1,059: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Portal hypertension]] | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Portal hypertension]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,133: | Line 1,097: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Age range | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | ||
Line 1,159: | Line 1,122: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,189: | Line 1,151: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,219: | Line 1,180: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,249: | Line 1,209: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,280: | Line 1,239: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,307: | Line 1,265: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,337: | Line 1,294: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |HELLP syndrome | ! colspan="2" align="center" style="background:#DCDCDC;" + |HELLP syndrome | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 16:08, 15 August 2018
Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thrombocytopenia differential diagnosis On the Web |
American Roentgen Ray Society Images of Thrombocytopenia differential diagnosis |
Risk calculators and risk factors for Thrombocytopenia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farbod Zahedi Tajrishi, M.D.
Overview
Thrombocytopenia has a broad range of potential causes. While a good history and physical examination can be helpful to diagnose some of these causes such as drug-induced thrombocytopenia, they usually don't suffice and further evaluation is often needed. There are also some useful points that may guide the physician to an appropriate diagnosis. For example, asymptomatic, isolated thrombocytopenia most probably suggests ITP, while thrombocytopenia in critically ill, hospitalized patients is usually suggestive of iatrogenic causes (eg. dilution), platelet consumption, bone marrow suppression from infection/sepsis, or even drug-induced thrombocytopenia. One should consider however, that a wide variety of other conditions such as autoimmune disorders, nutrient deficiencies, thrombotic microangiopathies could all as well cause thrombocytopenia.
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age range | History | Symptoms | Signs | ||||||||||||||||||||||||||
Lab Findings | Imaging | ||||||||||||||||||||||||||||
Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | BT | UA | ||||||||||||||||
Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Plt | HB | WBC | ||||||||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes | + | ||||||||||||||||||||||||||
Aplastic anemia | + | ||||||||||||||||||||||||||||
Acute leukemia | + | ||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | + | ||||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | + | |||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | + | ||||||||||||||||||||||||||||
DIC | + | ||||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | ||||||||||||||||||||||||||||
Bernard-Soulier syndrome | |||||||||||||||||||||||||||||
Gray platelet syndrome | |||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | |||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | |||||||||||||||||||||||||||||
Alport syndrome | |||||||||||||||||||||||||||||
Von Willebrand disease | |||||||||||||||||||||||||||||
Nutrient deficiencies | Folate, vitamin B12, copper | + | |||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Age range | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Rheumatologic/autoimmune disorders | Immune thrombocytopenia | Antibody-mediated platelet destruction | + | ||||||||||||||||||||||||||
Systemic lupus erythematosus (SLE) | + | ||||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | Autoantibody-mediated syndrome | + | |||||||||||||||||||||||||||
Felty's syndrome | Splenomegaly | + | |||||||||||||||||||||||||||
Infection-induced | Bacterial infections | Sepsis | Direct bone marrow suppression | + | + | ↑ | ↑ | ||||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | + | |||||||||||||||||||||||||||
Tick-borne infection | + | ||||||||||||||||||||||||||||
Viral infections | HIV | An ITP-like condition called primary HIV-associated thrombocytopenia | + | + | + | ||||||||||||||||||||||||
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | + | ||||||||||||||||||||||||||||
Parasitic infections | Malaria | ||||||||||||||||||||||||||||
Babesiosis | |||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Age range | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Medication/toxicity | Antibiotics/ | Occurrence of drug-dependent, platelet-reactive antibodies | + | + | |||||||||||||||||||||||||
Heparin-induced thrombocytopenia | Anti-heparin/PF4 antibody | + | ELISA | Early or delayed-onset | |||||||||||||||||||||||||
Cytotoxic chemotherapy | + | ||||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | + | |||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | ||||||||||||||||||||||||||||
GI | Chronic liver disease | + | |||||||||||||||||||||||||||
Portal hypertension | |||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in blood | Platelet destruction in spleen | Inherited | Acquried | Age range | History | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Vascular | Giant capillary hemangioma | Platelet destruction | + | ||||||||||||||||||||||||||
Aortic aneurysm | Platelet destruction | + | |||||||||||||||||||||||||||
Cardiopulmonary bypass | Platelet destruction | + | |||||||||||||||||||||||||||
Other | Alcohol | + | |||||||||||||||||||||||||||
Post-transfusion purpura | Immune mediated platelet destruction | + | |||||||||||||||||||||||||||
Gestational thrombocytopenia | |||||||||||||||||||||||||||||
HELLP syndrome |